{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "UCH-L1",
        "Protein_Change": {
          "ref": "I",
          "alt": "M",
          "position": "93"
        },
        "variant_string_id": "UCH-L1 I93M"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper links UCH-L1 secretion to Parkinson's disease pathology, stating that the hydrolase activity is not necessary for unconventional secretion and that secretion may contribute to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly connects UCH-L1 secretion to PD pathology, defining the disease mechanism as impaired secretion affecting neuronal function."
        },
        {
          "step_name": "Step 2: Evaluate applicability of assay",
          "extracted_paper_info": "The assay examines UCH-L1 secretion and its modulation by a-synuclein mutants, directly relevant to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The secretion assay models the disease mechanism by showing how UCH-L1 dysfunction (e.g., I93M) and a-synuclein mutations affect secretion, a key factor in PD."
        },
        {
          "step_name": "Step 3: Variant controls",
          "extracted_paper_info": "The paper uses wild-type UCH-L1 and known PD-associated mutations (I93M) as controls, with no explicit mention of benign variant controls.",
          "judgment": "No",
          "reasoning": "Variant controls were not explicitly used for I93M, limiting the strength of functional evidence."
        },
        {
          "step_name": "Step 4: Correlate OddsPath",
          "extracted_paper_info": "The paper reports reduced secretion for I93M but lacks statistical analysis or OddsPath calculation.",
          "judgment": "No",
          "reasoning": "No OddsPath calculation was performed, so the strength is based on the number of variant controls."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study uses a limited number of variant controls (e.g., I93M and a-synuclein mutants), likely fewer than 11.",
          "judgment": "10 or less",
          "reasoning": "The paper does not explicitly report the number of variant controls used, but the results are based on a single pathogenic variant (I93M) and its effect on secretion."
        }
      ],
      "type": "PS3",
      "strength": "PS3_supporting",
      "overall_conclusion": "The I93M variant reduces UCH-L1 secretion, consistent with PD pathogenesis. While variant controls are limited, the functional effect aligns with disease mechanisms, supporting pathogenicity."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper links a-synuclein mutations (e.g., A30P) to PD by showing their ability to reduce UCH-L1 secretion, a key factor in PD pathology.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is defined as a-synuclein mutations disrupting UCH-L1 secretion, contributing to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of assay",
          "extracted_paper_info": "The assay examines the interaction between a-synuclein mutants and UCH-L1 secretion, directly relevant to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The assay models how a-synuclein mutations (e.g., A30P) modulate UCH-L1 secretion, a critical pathway in PD."
        },
        {
          "step_name": "Step 3: Variant controls",
          "extracted_paper_info": "The paper uses wild-type SNCA and known PD-associated mutations (e.g., A30P) as controls, with no explicit mention of benign variant controls.",
          "judgment": "No",
          "reasoning": "Variant controls were not explicitly used for A30P, limiting the strength of functional evidence."
        },
        {
          "step_name": "Step 4: Correlate OddsPath",
          "extracted_paper_info": "The paper reports reduced UCH-L1 secretion for A30P but lacks statistical analysis or OddsPath calculation.",
          "judgment": "No",
          "reasoning": "No OddsPath calculation was performed, so the strength is based on the number of variant controls."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study uses a limited number of variant controls (e.g., A30P and other a-synuclein mutants), likely fewer than 11.",
          "judgment": "10 or less",
          "reasoning": "The paper does not explicitly report the number of variant controls used, but the results are based on a single pathogenic variant (A30P) and its effect on secretion."
        }
      ],
      "type": "PS3",
      "strength": "PS3_supporting",
      "overall_conclusion": "The A30P variant reduces UCH-L1 secretion, consistent with PD pathogenesis. While variant controls are limited, the functional effect aligns with disease mechanisms, supporting pathogenicity."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper links a-synuclein mutations (e.g., A53T) to PD by showing their ability to reduce UCH-L1 secretion, a key factor in PD pathology.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is defined as a-synuclein mutations disrupting UCH-L1 secretion, contributing to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of assay",
          "extracted_paper_info": "The assay examines the interaction between a-synuclein mutants and UCH-L1 secretion, directly relevant to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The assay models how a-synneuclein mutations (e.g., A53T) modulate UCH-L1 secretion, a critical pathway in PD."
        },
        {
          "step_name": "Step 3: Variant controls",
          "extracted_paper_info": "The paper uses wild-type SNCA and known PD-associated mutations (e.g., A53T) as controls, with no explicit mention of benign variant controls.",
          "judgment": "No",
          "reasoning": "Variant controls were not explicitly used for A53T, limiting the strength of functional evidence."
        },
        {
          "step_name": "Step 4: Correlate OddsPath",
          "extracted_paper_info": "The paper reports reduced UCH-L1 secretion for A53T but lacks statistical analysis or OddsPath calculation.",
          "judgment": "No",
          "reasoning": "No OddsPath calculation was performed, so the strength is based on the number of variant controls."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study uses a limited number of variant controls (e.g., A53T and other a-synuclein mutants), likely fewer than 11.",
          "judgment": "10 or less",
          "reasoning": "The paper does not explicitly report the number of variant controls used, but the results are based on a single pathogenic variant (A53T) and its effect on secretion."
        }
      ],
      "type": "PS3",
      "strength": "PS3_supporting",
      "overall_conclusion": "The A53T variant reduces UCH-L1 secretion, consistent with PD pathogenesis. While variant controls are limited, the functional effect aligns with disease mechanisms, supporting pathogenicity."
    }
  ]
}